Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2023-11-15 Regulatory Filings
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
Regulatory Filings Classification · 100% confidence The document is a press release dated November 15, 2023, announcing that Heidelberg Pharma AG has secured a patent for its ADC technology platform from the European Patent Office (EPO). It contains standard press release formatting, contact information, and forward-looking statements, disseminated via EQS News. This type of announcement, which is a specific corporate update (patent grant) but does not fit neatly into the defined financial reporting categories (like 10-K, ER, IR), is best classified as a general Regulatory Filing or Corporate News announcement. Since 'Regulatory Filings (RNS)' is defined as the fallback for miscellaneous filings that do not neatly fit, and this is a specific corporate event announcement rather than a financial report, RNS is the most appropriate code.
2023-11-15 English
Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
Regulatory Filings Classification · 100% confidence The document is a press release dated November 2, 2023, announcing that Heidelberg Pharma will present new clinical data for its candidate HDP-101 at the ASH Annual Meeting 2023. It details the presentation time, abstract number, and provides background on the drug technology. This type of announcement, which publicizes upcoming scientific presentations or data releases, is generally classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it were financial results. However, since this is an announcement about presenting clinical data at a medical conference, it is most closely aligned with providing specific, non-financial operational/scientific updates to investors. Given the options, and recognizing that it is not a formal regulatory filing (like 10-K or IR) nor a general regulatory news item (RNS), it functions as a specific update intended for the investment community regarding clinical progress. In the context of these specific codes, Investor Presentation (IP) is the best fit as it relates to presenting detailed scientific/clinical information to investors, even if the actual presentation is at a third-party conference. It is not a Call Transcript (CT), Earnings Release (ER) (as it's clinical data, not financial results), or a Report Publication Announcement (RPA) because it is announcing the presentation of data, not the publication of a formal company report.
2023-11-02 English
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
Earnings Release Classification · 100% confidence The document is explicitly titled 'Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023'. It details operational developments, financial figures, and business performance for the period from December 1, 2022, to August 31, 2023 (9M 2023). This content structure—a comprehensive report covering a period shorter than a full fiscal year (nine months) with detailed financial results and management commentary—perfectly matches the definition of an Interim/Quarterly Report. The code for this is 'IR'. It is not a brief announcement of a report (RPA/RNS), as the document contains substantial detail. 9M 2023
2023-10-12 English
Quartalsfinanzbericht
Interim / Quarterly Report Classification · 100% confidence The document is a 'Zwischenmitteilung' (Interim Report) for the first nine months of 2023 for Heidelberg Pharma AG. It contains detailed financial performance, operational updates, clinical trial progress, and management commentary. It is a comprehensive report covering a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-10-12 German
Q3 statement / Q3 financial report 2022/2023
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim Management Statement' for Heidelberg Pharma AG covering the first nine months of the 2023 fiscal year. It provides a detailed narrative of operational developments, clinical trial progress, and a section titled 'Results of operations, financial position and net assets' which includes specific financial figures (sales revenues, operating expenses, R&D costs). Because it covers a period shorter than a full fiscal year and contains substantive financial data and management analysis, it qualifies as an Interim/Quarterly Report. 9M 2023
2023-10-12 English
Heidelberg Pharma AG: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
Earnings Release Classification · 99% confidence The document is a press release dated September 19, 2023, providing an update on a clinical trial (Phase I/IIa) for a drug candidate (HDP-101). It details safety data, dose escalation progress, and future plans for the study. This type of announcement, focusing on operational or clinical progress rather than mandated periodic financial reporting (like 10-K or IR), is typically classified as a general Regulatory Filing or News Release. Since it is not a formal earnings release (ER), a management discussion (MDA), or a specific regulatory filing like DIRS or DIV, and it is a direct announcement of company news, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for non-standard, material corporate news disseminated via services like EQS News. FY 2023
2023-09-19 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.